The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialJason J. Luke, Paul A. Moore, Bartosz Chmielowski et al.|Nature Medicine|2023Cited by 135
Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal CancerPaul A. Moore, Syd Johnson, Kalpana Shah et al.|Molecular Cancer Therapeutics|2018Cited by 76